To address difficulties in distinguishing between HER2-low and HER2-zero, pathologists have already pointed out possible solutions for the assessment of immunohistochemical staining such as (1) application of the “magnification rule”, (2) staining pattern-circularity of membrane staining, and (3) percentage of tumor cells with HER2 expression [42]. Here, ERBB2 is linked to neoplasm.